SANUWAVE Health, Inc. Provides Revenue Guidance for the First Quarter of 2023
April 03, 2023 at 12:30 pm
Share
SANUWAVE Health, Inc. provided revenue guidance for the first quarter of 2023. For the quarter, the company has anticipate revenue growth of approximately 14 to 20% during this quarter compared to First Quarter 2022, ended March 31, 2022. The company believes that supply constraint has been meaningfully alleviated and that Second Quarter 2023 should see further increase in revenue growth.
Sanuwave Health, Inc. is an ultrasound and shock wave technology company. The Company is a provider of Food and Drug Administration (FDA)-approved wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. The Company applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and others. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing from within. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression (PACE) technology to converge at precise selected targets to produce an extremely short duration compression burst.
SANUWAVE HEALTH, INC. 
